Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Organovo Hol ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

SAN DIEGO, CA, USA I5, 2025 I Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused ...

Eli Lilly (LLY) on Wednesday outlined a plan to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the US. The pharmaceutical giant said that three of the planned ...

US equity indexes ended mixed on Tuesday, with an afternoon rebound carrying blue-chip stocks back to positive ground and paring earlier losses for other major market gauges after the Conference Board ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

China needs to tackle its steel glut by cutting 15% of capacity this year, if mills are to meet their 2025 climate goals and ...